Overview

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of volociximab intravitreous injection in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Phase:

Phase 1

Details

Lead Sponsor:

Ophthotech Corporation

Treatments:

Antibodies, Monoclonal
Volociximab